Bypass Surgery Articles & Analysis
11 news found
The good news for his patient was that she was young. A lower extremity bypass procedure - like any surgery - can be more difficult as we age. The bad news was that the best veins for the procedure - which involves grafting a vein from another part of the body to bypass her blocked arteries in the leg - were unusable. The patient had ...
XyloCor also plans to study XC001 in other patient groups as well, including as adjunctive therapy in patients undergoing bypass surgery.” Individuals with refractory angina experience pressure or intense pain in the chest due to insufficient blood flow to the heart muscle. ...
The disease that Villix first targeted is ischemic reperfusion injury that occurs in organ transplant myocardial infarction, coronary artery bypass surgery, and stroke. Myocardial infarction occurs after the patient has undergone stenting. ...
These patients experience frequent angina (chest pain) attacks that are uncontrolled by optimal drug therapy but are not suitable candidates for stent placement or bypass surgery, leaving them with no therapeutic options. The first patient was treated with the investigational CardiAMP autologous cell therapy at the University of Wisconsin in Madison, by ...
Company closes additional $22.6 million in new financing Proceeds will fund initiation of new clinical trial for lead gene therapy candidate XC001 as adjunctive therapy for patients undergoing coronary artery bypass graft surgery XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for the ...
Postoperative complications in major surgery are the most significant independent risk factor leading to high morbidity and hospital readmissions. Following the completion of two Phase II surgery trials in ECS and coronary artery bypass graft surgery, and a final European Medicines Agency advice letter, a European pivotal trial ...
Postoperative complications in major surgery are the most significant independent risk factor leading to high morbidity and hospital readmissions. Following the completion of two Phase II surgery trials in ECS and coronary artery bypass graft surgery, and a final European Medicines Agency advice letter, a European pivotal trial ...
About Heartcel Heartcell is an allogeneic cell therapy containing off-the-shelf immunomodulatory progenitor (iMP) cells engineered to regenerate the heart. iMPs are administered during coronary artery bypass graft (CABG) surgery by direct injection around the cardiac scar that is to be regenerated. iMP cells have been designated an Advanced Therapeutic Medicinal ...
Heart failure affects 26 million people worldwide.1 Patients with severe heart failure have impaired quality of life with approximately 70% of this patient group dying within a year.2 It remains incurable and current treatment options, including bypass surgery, only go some way into alleviating the symptoms. However, recent advances in regenerative medicine may ...
The condition features a progressive degenerative scarring of the heart associated with significant mortality and morbidity.2 iMP cells were injected into the cardiac scar during bypass surgery in a Phase 2 clinical trial of 11 severe heart failure patients at high risk of incomplete re-vascularisation (ICR).1 At 12 months following treatment, results ...
This last tissue type was obtained from morbidly obese patients undergoing bypass surgery. In one round of experiments they placed small pieces of the tissue in plates and exposed them to different concentrations of BPA and estradiol. ...